Abstract:Abstract Background Dihydroartemisinin (DHA), a derivate of artemisinin, is an effective antimalarial agent. DHA has been shown to exert anticancer activities to numerous cancer cells in the past few years, while the exact molecular mechanisms remain to be elucidated, especially in esophageal cancer. Methods Crystal violet assay was conducted to determine the cell viability of human esophageal cancer cell line Eca109 treated with DHA. Tumor-bearing nude mice were employed to evaluate the anticancer effect of DHA in vivo. Soft agar and crystal violet assays were used to measure the tumorigenicity of Eca109 cells. Flow cytometry was performed to evaluate ROS or cell cycle distribution. GFP-LC3 plasmids were delivered into Eca109 cells to visualize autophagy induced by DHA under a fluorescence microscope. The mRNA and protein levels of each gene were tested by qRT-PCR and western blot, respectively. Results Our results proved that DHA significantly reduced the viability of Eca109 cells in a dose- and time-dependent manner. Further investigation showed that DHA evidently induced cell cycle arrest at the G2/M phase in Eca109 cells. Mechanistically, DHA induced intracellular ROS generation and autophagy in Eca109 cells, while blocking ROS by an antioxidant NAC obviously inhibited autophagy. Furthermore, we found that telomere shelterin component TRF2 was down-regulated in Eca109 cells exposed to DHA through autophagy-dependent degradation, which could be rescued after autophagy was blocked by ROS inhibition. Moreover, the DNA damage response (DDR) was induced obviously in DHA treated cells. To further explore whether ROS or autophagy played a vital role in DHA induced cell cycle arrest, the cell cycle distribution of Eca109 cells was evaluated after ROS or autophagy blocking, and the results showed that autophagy, but not ROS, was essential for cell cycle arrest in DHA treated cells. Conclusion Taken together, DHA showed anticancer effect on esophageal cancer cells through autophagy-dependent cell cycle arrest at the G2/M phase, which unveiled a novel mechanism of DHA as a chemotherapeutic agent, and the degradation of TRF2 followed by DDR might be responsible for this cell phenotype.

Dihydroartemisinin Induces Autophagy by Suppressing NF-κB Activation

Dihydroartemisinin Induces Endothelial Cell Autophagy through Suppression of the Akt/mTOR Pathway.

Dihydroartemisinin Induces Endothelial Cell Autophagy Through Suppression of the Akt/mTOR Pathway

Dihydroartemisinin Induces Autophagy and Inhibits the Growth of Iron-Loaded Human Myeloid Leukemia K562 Cells Via ROS Toxicity.

Novel dihydroartemisinin derivative DHA-37 induces autophagic cell death through upregulation of HMGB1 in A549 cells

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma Through the P38/MAPK and Wnt/β-Catenin Signaling Pathways.

[Dihydroartemisinin Induces Autophagic Cell Death in Acute Myeloid Leukemia Cells through Oxidative Stress]

Anticancer Effect of Dihydroartemisinin via Dual Control of ROS-induced Apoptosis and Protective Autophagy in Prostate Cancer 22Rv1 Cells

Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin

Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

P8 Attenuates the Apoptosis Induced by Dihydroartemisinin in Cancer Cells Through Promoting Autophagy.

Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases

Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells

Dihydroartemisinin Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Hepg2 Human Hepatoma Cells

Growth Inhibitory Effects of Dihydroartemisinin on Pancreatic Cancer Cells: Involvement of Cell Cycle Arrest and Inactivation of Nuclear Factor-Κb

Dihydroartemisinin Enhances Apo2l/Trail-Mediated Apoptosis in Pancreatic Cancer Cells Via Ros-Mediated Up-Regulation of Death Receptor 5

Dihydroartemisinin Induces Apoptosis of Cervical Cancer Cells Via Upregulation of RKIP and Downregulation of Bcl-2.

Single-cell Analysis of Dihydroartemisinin-Induced Apoptosis Through Reactive Oxygen Species-Mediated Caspase-8 Activation and Mitochondrial Pathway in ASTC-a-1 Cells Using Fluorescence Imaging Techniques.

Dihydroartemisinin Suppresses Pancreatic Cancer Cells Via a Microrna-Mrna Regulatory Network

Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway

Dihydroartemisinin Inactivates Nf-Kappa B and Potentiates the Anti-Tumor Effect of Gemcitabine on Pancreatic Cancer Both in Vitro and in Vivo